Accordingly, WDR5 is an auspicious target for inhibition in a range of malignancies including MLL-rearranged (MLLr) leukemias (Cao et al., 2014; Aho et al., 2019a), MYC-driven cancers (Aho et al., 2019b), C/EBPα-mutant leukemias (Grebien et al., 2015), p53 gain-of-function cancers (Zhu et al., 2015), neuroblastomas (Bryan et al., 2020), rhabdoid tumors (Florian et al., 2022), and metastatic breast cancers (Cai et al., 2022). The gene discussed is KMT2A; the disease is cancer.